Supercharge your antioxidant defense with SugarMD R-Alpha Lipoic Acid (R-ALA), a premium, bioavailable formula designed to help neutralize free radicals and support overall cellular health¹. Unlike traditional antioxidants, R-ALA has the unique ability to regenerate antioxidants like vitamins C and E², extending their protective effects against oxidative stress. This makes R-ALA particularly beneficial for individuals seeking to support balanced blood sugar levels, promote nerve health³, and enhance overall resilience.

As the natural form of alpha-lipoic acid found in the body, R-ALA ensures superior bioavailability, allowing your body to absorb and utilize this powerful antioxidant more effectively. SugarMD R-Alpha Lipoic Acid is your trusted choice for targeted antioxidant support in an easy-to-absorb formula.

Disclaimer:

This supplement is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. Consult your healthcare provider before use, especially if pregnant, nursing, taking medications, or managing a medical condition. Not for individuals under 18. Gallery images are for reference only, not to scale, and may not show all ingredients. Actual product details may vary.

Quality Commitment:

At SugarMD, “Lab Tested for Purity” means every ingredient undergoes rigorous testing to ensure it’s free from contaminants like pesticides and heavy metals. We prioritize only the cleanest, most natural ingredients, crafted to meet high wellness standards so you can trust SugarMD for yourself and those you care about.

1. Ziegler, Dan, Phillip A. Low, William J. Litchy, Andrew J. M. Boulton, Aaron I. Vinik, Roy Freeman, Rustem Samigullin, Hans Tritschler, Ullrich Munzel, and Joachim Maus. “Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 Trial.” Diabetes Care 34, no. 9 (2011): 2054-2060.
2. Linus Pauling Institute. “Lipoic Acid.” Micronutrient Information Center, Oregon State University. Accessed January 8, 2025.
3. Ziegler, Dan, Phillip A. Low, William J. Litchy, Andrew J. M. Boulton, Aaron I. Vinik, Roy Freeman, Rustem Samigullin, Hans Tritschler, Ullrich Munzel, and Joachim Maus. “Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 Trial.” Diabetes Care 34, no. 9 (2011): 2054-2060.